On Wednesday morning, Horizon Therapeutics (NASDAQ: HZNP) announced its fourth-quarter and full-year financial results. Thanks to strong sales of its top drug, a gout treatment known as Krystexxa, the company beat both its revenue and earnings estimates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,